David A. Arkowitz
Independent DirectorMr. David A. Arkowitz, M.B.A. has been an Independent Director of iBio, Inc. since November 21, 2024. He is Chief Financial Officer of Alkeus Pharmaceuticals, Inc. from October 2024. He joined Alkeus Pharmaceuticals, Inc. in October 2024. He served as an Independent Director at Kineta Inc. since December 16, 2022 until June 30, 2025. He had been Executive Vice President, Chief Financial Officer and Head of Business Development at Seres Therapeutics, Inc. since June 01, 2021 until March 25, 2024. He was a Director at F-star Therapeutics, Inc since November 20, 2020. He served as Chief Financial Officer of Flexion Therapeutics, Inc. since May 7, 2018 until May 2021 and served as its Treasurer and had responsibility for the finance and accounting, corporate communications and Investor Relations, information technology and Chemistry, Manufacturing and Controls (CMC) functions. Mr. Arkowitz served as the Chief Financial Officer and Chief Operating Officer at Visterra, Inc. since September 2013 until May 7, 2018, here he led the finance, business development, corporate planning and other functions. Mr. Arkowitz served as the Chief Financial Officer of Mascoma Corporation since June 14, 2011 until September 2013 and its Treasurer and Secretary since July 2011 until September 2013. He served as General Manager, Mascoma Grain Tech. He served as Independent Director at Yumanity Therapeutics, Inc. since December 22, 2020 until December 2022. Mr. Arkowitz served as the Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, Inc. from April 5, 2007 to June 24, 2011 and also served as its Principal Accounting Officer, Executive Vice President and Treasurer until June 24, 2011. He was responsible for all finance, treasury, business development and Investor Relations functions at AMAG Pharmaceuticals. He has finance leadership experience in the healthcare, life sciences and biotechnology industries. He served as Chief Financial Officer of Idenix Pharmaceuticals Inc. from December 2003 to March 30, 2007 and served as its Treasurer from January 2004 to March 30, 2007 as well as its Principal Accounting Officer until March 30, 2007. Mr. Arkowitz was with Merck & Co. Inc. in a variety of financial leadership positions. He served as Vice President & Controller of the global research and development division and CFO of the Canadian subsidiary at Merck U.S. Human Health from September 2002 to December 2003, where he provided financial leadership to the marketing and sales operations in the United States, Merck's largest market. In this role, Mr. Arkowitz was a key contributor to the spin-off of Medco Health, completed August 2003 and the establishment of a new distribution program for U.S. wholesalers. Mr. Arkowitz held several senior finance and business development positions at Merck-Medco Managed Care, LLC, including Vice President of Financial Planning & Analysis and Vice President of Business Development and also served as Director of Financial Evaluation and Analysis, where he played a key role in Merck's acquisition of Medco Containment Services in 1993. He served as an Independent Director of Spring Bank Pharmaceuticals, Inc. since January 28, 2014. He served as a Director of Proteostasis Therapeutics, Inc. since March 6, 2019 until December 2020. He served as a Director of Impactrx, Inc. since August 2005. He served as Director of Aegerion Pharmaceuticals, Inc. since May 2007. Mr. Arkowitz holds a M.B.A. in Finance from Columbia University Business School and a B.A. in Mathematics from Brandeis University.
Positions
- Company NameiBio, Inc.Stock CodeIBIOPositionIndependent DirectorColleagues
- MBMartin B. BrennerCEO, Chief Scientific Officer & Director
- WDWilliam D. ClarkIndependent Chairman
- FDFelipe DuranCFO & Principal Accounting Officer
- MBMarc BanjakChief Legal Officer & Corporate Secretary
- MCMolly CarrChief Medical Officer
- AKAlexandra KropotovaIndependent Director
- GLGary L. SenderIndependent Director
